https://www.selleckchem.com/pr....oducts/Sunitinib-Mal
Examine the trajectory of left ventricular ejection fraction (EF) among patients eligible for implantable cardioverter-defibrillator (ICD) therapy. EF is the cornerstone criterion for ICD therapy, but the risk of sudden cardiac death remains after an improvement in EF. We examined the trajectory of EF among 1178 participants of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) who had three or more assessments of EF, at least 90 days apart. A follow-up EF35% or10% absolute increase in EF from baseline
Like
Comment
Share
